Company / SG&A Expense
PLUS THERAPEUTICS, INC. SG&A Expense History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$9.9M
FY2025
5-year range
$7.6M / $9.9M
FY2021-FY2025
Trend
+16.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $8M to $10M over the past 7 years.
Based on SEC 10-K filings.
$10M in FY2025 with a 10-year CAGR of -4.7%.
Increased from $8M to $10M over the past 7 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -4.7%
Key checks
Key Insights
- In FY2025, sg&a expense increased 16.3% year-over-year.
- Peak sg&a expense was recorded in FY2015.
- Lowest sg&a expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -2.46 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.9M | +16.3% |
| FY2024 | $8.5M | +12.5% |
| FY2018 | $7.6M | -11.3% |
| FY2017 | $8.6M | -12.3% |
| FY2016 | $9.8M | -39.1% |
| FY2015 | $16.0M | +2.3% |
| FY2014 | $15.7M | +6.4% |
| FY2013 | $14.7M | +17.2% |
| FY2012 | $12.6M | +20.7% |
| FY2011 | $10.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026